RecruitingCOPD
Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
Eligible age
22+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
Sponsor: Fisher and Paykel Healthcare
You may qualify if…
- ✓ Has cognitive ability to provide informed consent
- ✓ Aged 22 years or older
- ✓ Hospitalized with hypoxemia/respiratory distress
- ✓ Diagnosis of COPD
- ✓ Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator
- ✓ Expected duration of oxygen and nasal high flow therapy \>24 hours (not necessarily continuous)
You may not qualify if…
- ✕ Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines
- ✕ Hemodynamic instability (systolic blood pressure \<90mmHg or requirement for vasopressor or inotropic support)
- ✕ Patient receiving end of life care
- ✕ Nasal or facial conditions precluding use of nasal high flow
- ✕ Pregnancy or breastfeeding
- ✕ Cognitive impairment or impaired consciousness precluding informed consent
- ✕ Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator
- ✕ Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included
Where it's recruiting
Source: ClinicalTrials.gov · NCT07222410 · last updated 2026-06-23